{"Clinical Trial ID": "NCT00068341", "Intervention": ["INTERVENTION 1:", "Bras I: HER2+", "(Pre-Op TCH)", "INTERVENTION 2:", "Bras II: HER2+", "(Pre-Op TC, post-Op Herceptin)"], "Eligibility": ["Incorporation criteria:", "Adenocarcinoma confirmed breast infiltrator", "\u2022 Primary breast cancer > 5cm, or skin/chest wall damage, any N, without evidence of metastasis.", "No previous radiation on the breast in question", "ECOG (Electrocochleography) performance status 0-2", "From 18 to 80 years of age", "Absolute neutrophil count > 1500 cells/\u03bcl, platelet count > 100,000 cells/\u03bcl and hemoglobin > 9 g/dl", "All liver function tests < upper limit of normal", "Serum creatinine < 2.0 mg/dl", "The normal left ventricular ejection fraction (LVEF) as determined by MUGA analysis or echocardiogram (Multiple Gated Acquisition)", "The HER-2/neu status is determined by a FISH (Fluorescence in situ) hybridization test. [FISH (+) is HER-2/neu (+)]", "If the woman of childbearing potential, the pregnancy test is negative", "In case of premenopausity and not surgical sterilization, the patient agrees to use an effective method of contraception throughout the study.", "Informed consent was obtained", "- Exclusion criteria:", "\u2022 Unconfirmed infiltrator adenocarcinoma breast cancer", "Evidence of metastases", "Previous chemotherapy using the medicinal products proposed in this study, in particular Herceptin\u00ae, Taxotere\u00ae and/or Carboplatin", "Previous radiation in the breast at issue", "A recent pharmacotherapy against breast cancer in the last 5 years of any form", "History of allergy to polysorbate or castor oil", "\u2022 Continuous active infection", "\u2022 Concomitant life-limiting illness with life expectancy less than one year", "Previous or current history of other malignancies in the past 5 years that may affect the diagnosis or assessment of breast cancer, with the exception of curatively treated non-melanoma skin cancer and/or in situ cervix carcinoma", "Pregnancy, breast-feeding, fertile women who do not use contraceptives", "Unable to give informed consent", "Patients with pre-existing peripheral neuropathy > grade 2"], "Results": ["Performance measures:", "To evaluate the objective response rate of patients treated with taxoterus/carboplatin with or without preoperative Herceptin.", "The objective response rate of patients treated with Taxotere/carboplatin with or without Preoperative Herceptin is equal to the combination of complete response (CR), partial response (PR) and marginal response (MR).", "The tumour size was evaluated by (1) physical examination, (2) mammography and (3) MRI. 5 response groups: complete response (CR), partial response (PR), marginal response (MR), stable disease (SD) and disease progression (PD).", "Time limit: 5 years", "Results 1:", "Title of arm/group: arms I: HER2+", "Description of arm/group: (pre-operation TCH)", "Total number of participants analysed: 15", "Type of measurement: Number", "Unit of measure: DFS participants (Survival without disease): 13", "OS (overall survival): 13", "Results 2:", "Title of arm/group: Arm II: HER2+", "Description of the arm/group: (Pre-Op TC, post-Op Herceptin)", "Total number of participants analysed: 14", "Type of measurement: Number", "Unit of measure: DFS participants (Survival without disease): 8", "Operating system (overall survival): 11"], "Adverse Events": ["Undesirable Events 1:", "Total: 6/15 (40.00 per cent)", "Diarrhoea and dehydration * 0/15 (0.00 %)", "Severe dehydration * 1/15 (6.67%)", "Hypokalaemia * 1/15 (6.67 per cent)", "Pain, swelling, mastectomy site cellulitis * 0/15 (0.00 %)", "* 0/15 (0.00 per cent)", "Abscess diver * 0/15 (0.00 %)", "Fever * 1/15 (6.67 per cent)", "Febrile neutropenia * 3/15 (20.00%)", "Neutropenia * 0/15 (0.00 %)", "Adverse Events 2:", "Total: 4/14 (28.57 per cent)", "Diarrhoea and dehydration * 0/14 (0.00 %)", "Severe dehydration * 0/14 (0.00 %)", "Hypokalaemia * 0/14 (0.00 %)", "Pain, swelling, mastectomy site cellulitis * 0/14 (0.0%)", "* 1/14 (7.14 per cent)", "Abscess diver * 0/14 (0.00 %)", "Fever * 0/14 (0.00 %)", "Febrile neutropenia * 2/14 (14.29%)", "Neutropenia * 0/14 (0.00 %)"]}